Introduction {#Sec1}
============

Adalimumab (reference product: Humira^®^; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany), a recombinant IgG1 monoclonal antibody that selectively blocks the activity of human tumor necrosis factor (TNF-alpha), is approved for the treatment of several diseases including rheumatoid, juvenile idiopathic, and psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa \[[@CR1]\]. Adalimumab specifically binds TNF-alpha to inhibit its interaction with cell surface receptors \[[@CR1]\] and to reduce inflammatory and autoimmune responses \[[@CR2], [@CR3]\]. Biosimilars, which are highly similar to biological originators, are being developed to help decrease costs associated with the use of reference products \[[@CR4]\]. SB5 (Imraldi^®^; Samsung Bioepis NL, Delft, The Netherlands) has an identical amino acid sequence as well as similar physicochemical and in vitro functional properties as the reference adalimumab (ADA) \[[@CR5], [@CR6]\]. A phase I study compared the pharmacokinetics (PK) of SB5 with ADA (European Union- and United States-sourced) and found similar PK profiles for all three compounds in healthy subjects \[[@CR7]\]. Furthermore, results from a phase III, randomized, double-blind study reported equivalent efficacy and comparable safety between SB5 and ADA in patients with rheumatoid arthritis \[[@CR8]\].

Adalimumab and the ADA biosimilars, Amgevita™ (Amgen Europe, Breda, The Netherlands), Hyrimoz^®^ (Sandoz GmbH, Kundl, Austria), Cyltezo^®^ (Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany), and Hulio^®^ (Mylan S.A.S., Saint-Priest, France) have been approved to be stored for 24 months at 2--8 °C \[[@CR1], [@CR9]--[@CR12]\]. In circumstances where refrigeration is not available, these products may be stored at room temperature (25 °C), with protection from light, for ≤ 14 days \[[@CR1], [@CR9]--[@CR12]\]. These storage limitations may potentially pose inconvenience for patients who may face extended periods without continuous access to refrigeration. As such, there is a perceived need for longer storage at room temperature (25 °C).

Currently, SB5 is approved for storage for 36 months at 2--8 °C and may be stored at room temperature (25 °C) for a maximum period of 14 days \[[@CR13]\]. It should be noted that SB5 may only be used as indicated in the summary of product characteristics. The objective of this study was to evaluate the stability of SB5, aged to its shelf-life of 36 months, at room temperature (25 ± 2 °C) and 60 ± 5% relative humidity (RH) for a period of 4 weeks. These conditions, which differ from standard accelerated stability studies by using SB5 aged to its shelf-life, represent a worst-case scenario in terms of medication storage. Of interest was whether the physicochemical and biological quality attributes of SB5 were stable for a longer period of time at room temperature (25 ± 2 °C) than the 2 weeks reported for SB5 currently approved in the European Union.

Methods {#Sec2}
=======

This article does not contain any studies with human participants or animals performed by any of the authors.

Forty-six syringes (0.8 mL/syringe) for each of three batches were used for testing at each time point. SB5 aged for 36 months at 5 ± 3 °C was stored at room temperature (25 ± 2 °C) and 60 ± 5% RH for 4 weeks in light-protected conditions. SB5 stability was assessed at 0, 2, and 4 weeks of storage. The following categories were assessed: visual characteristics (color, clarity, visible particles), pH, chemical analysis (protein concentration), physicochemical analysis \[high molecular weight (HMW) impurities, overall purity, low molecular weight (LMW) impurities such as non-glycosylated heavy chain (NGHC), and charge isoforms\], subvisible particulates (particulate matter), and biological activity (TNF-alpha binding and neutralization). Table [1](#Tab1){ref-type="table"} summarizes the techniques used to assess each quality attribute.Table 1Summary of methods used for determining stability of SB5CategoryProduct quality attributeMethodObjectiveVisual characteristicColorVisual inspectionEvaluation of color using brown standard B1--B7ClarityTurbidity measurement by HACH Model 2100ANEvaluation of level of clarity of sampleVisible particlesVisual inspectionDetermination of number of visible particlespHpHpH measurement by Thermo Scientific Orion Star A211Evaluation of pHChemical analysisProtein concentrationA~280~ measurement by UV--VIS spectrophotometerDetermination of concentration of proteinPhysicochemical analysisHMW impuritiesSE-HPLCDetermination of the percentage of HMW impuritiesOverall purityCE-SDSDetermination of total purityLMW impuritiesCE-SDSDetermination of the presence of LMW impurities (e.g., NGHC)Charge isoformsCEX-HPLC, icIEFDetermination of the change in charge variance, including acidic, main, and basic variantsSubvisible particulatesParticulate matterHIAC 9703 + and HRLD-400Determination of the number of particles that are ≥ 25, ≥ 10Biological activityTNF-alpha binding activityFRETDetermination of the relative binding to the reference standardTNF-alpha neutralization activityLuciferase reporter gene system assayDetermination of the relative potency to the reference standard*A*~*280*~ absorbance at 280 nm, *CE-SDS* capillary electrophoresis-sodium dodecyl sulfate, *CEX-HPLC* cation exchange high-performance liquid chromatography, *FRET* fluorescence resonance energy transfer, *HMW* high molecular weight, *icIEF* imaged capillary isoelectric focusing, *LMW* low molecular weight, *NGHC* non-glycosylated heavy chain, *SE-HPLC* size-exclusion high-performance liquid chromatography, *TNF-alpha* tumor necrosis factor

Results {#Sec3}
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Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"} summarize the stability characteristics of batches at weeks 0, 2, and 4. Color, clarity, visible particles, pH, protein concentration, and particulate matter were consistent among batches, and all test results met the acceptance criteria at each time point.Table 2Stability of aged SB5 batch 1 at room temperature (25 ± 2 °C) and 60 ± 5% relative humidityCategoryTest itemTime point/sampling date (week)024GeneralColorB8 \< sample \< B7B9 ≤ sample \< B8B8 \< sample \< B7Clarity, NTU181917Visible particlesPractically free from particlesPractically free from particlesPractically free from particlespH5.35.35.2QuantityProtein concentration (A~280~), mg/mL50.850.851.7SafetyParticulate matter, particles/syringe≥ 25 µm101938≥ 10 µm131212041361The acceptance criteria of particulate matter are "Particle ≥ 10 μm: ≤ 6000/syringe" and "Particle ≥ 25 μm: ≤ 600/syringe" according to Ph. Eur. 2.9.19/\<USP 788\>*A*~*280*~ absorbance at 280 nm, *NTU* nephelometric turbidity unit Table 3Stability of aged SB5 batch 2 at room temperature (25 ± 2 °C) and 60 ± 5% relative humidityCategoryTest itemTime point/sampling date (week)024GeneralColorB7 ≤ Sample \< B6ColorlessB8 \< Sample \< B7Clarity, NTU161718Visible particlesPractically free from particlesPractically free from particlesPractically free from particlespH5.25.25.3QuantityProtein concentration (A~280~), mg/mL:50.549.050.4SafetyParticulate matter, particles/syringe≥ 25 µm142318≥ 10 µm136410891234The acceptance criteria of particulate matter are "Particle ≥ 10 μm: ≤ 6000/syringe" and "Particle ≥ 25 μm: ≤ 600/syringe" acccording to Ph. Eur. 2.9.19/\<USP 788\>*A*~*280*~ absorbance at 280 nm, *NTU* nephelometric turbidity unit Table 4Stability of aged SB5 Batch 3 at room temperature (25 ± 2 °C) and 60 ± 5% relative humidityCategoryTest itemTime point/sampling date (week)024GeneralColorB7 ≤ sample \< B6ColorlessB8 \< sample \< B7Clarity, NTU161717Visible particlesPractically free from particlesPractically free from particlesPractically free from particlespH5.25.25.3QuantityProtein concentration (A~280~), mg/mL51.449.450.4SafetyParticulate matter, particles/syringe≥25 µm131513≥10 µm14019231084The acceptance criteria of particulate matter are "Particle ≥ 10 μm: ≤ 6000//syringe" and "Particle ≥ 25 μm: ≤ 600/syringe" according to Ph. Eur. 2.9.19/\<USP 788\>*A*~*280*~ absorbance at 280 nm, *NTU* nephelometric turbidity unit

Figure [1](#Fig1){ref-type="fig"} shows the percent of HMW species (Fig. [1](#Fig1){ref-type="fig"}a), total purity (Fig. [1](#Fig1){ref-type="fig"}b), and percent of NGHC (Fig. [1](#Fig1){ref-type="fig"}c). Size-exclusion high-performance liquid chromatography (SE-HPLC) analysis showed a negligible increase (up to 0.1%) in the percent of HMW species after 4 weeks of storage at 25 ± 2 °C and 60 ± 5% RH for each SB5 batch; all values were within the acceptance criteria limits. A non-reducing capillary electrophoresis--sodium dodecyl sulfate (CE-SDS) was employed as an analytical method, which enabled complete resolution and better separation of incomplete antibody fragments and LMW variants compared to SE-HPLC. Total purity as measured by CE-SDS was not changed for any batch, and the level of LMW impurities did not change over the storage period, consistent with SE-HPLC data. There was no significant increase in the percent of NGHC, as measured by reduced CE-SDS, for any batch. Taken together, these results suggest there was no significant change in SB5 molecular weight variants over the 4-week study period.Fig. 1Stability trends of aged SB5 (batches 1, 2, and 3) at room temperature (25 ± 2 °C) and 60 ± 5% RH. **a** Percent of HMW species as measured by SE-HPLC. **b** Percent total purity as measured by CRE-SDS (NR). **c** Percent of NGHC as measured by reduced CE-SDS. *CE-SDS* capillary electrophoresis-sodium dodecyl sulfate, *HMW* high molecular weight, *NR* non-reduced, *RH* relative humidity, *SE-HPLC* size-exclusion high-performance liquid chromatography

Figure [2](#Fig2){ref-type="fig"} shows relative binding activity by TNF-alpha using fluorescence resonance energy transfer (Fig. [2](#Fig2){ref-type="fig"}a) and relative potency by TNF-alpha neutralization using an NF-κB reporter gene system (Fig. [2](#Fig2){ref-type="fig"}b). Over the 4-week period, the results of the relative binding assay and relative potency assay did not change significantly for any batch tested, suggesting that biological activity, including binding activity and potency, were maintained for 4 weeks. The results met the acceptance criteria for all batches.Fig. 2Stability trends of aged SB5 (batches 1, 2, and 3) at room temperature (25 ± 2 °C) and 60 ± 5% RH. **a** Percent relative binding activity by TNF-alpha. **b** Percent relative potency by TNF-alpha neutralization. *RH* relative humidity, *TNF* tumor necrosis factor

Figure [3](#Fig3){ref-type="fig"} shows the percent acidic charge (Fig. [3](#Fig3){ref-type="fig"}a, b), main charge (Fig. [3](#Fig3){ref-type="fig"}c, d), and basic charge (Fig. [3](#Fig3){ref-type="fig"}e, f). The percent acidic, main, and basic profile of SB5, as measured by cation exchange high-performance liquid chromatography (CEX-HPLC) and imaged capillary isoelectric focusing (icIEF), was similarly maintained for each batch over time.Fig. 3Stability trends of aged SB5 (batches 1, 2, and 3) at room temperature (25 ± 2 °C) and 60 ± 5% RH. Percent acidic variants as measured by **a** icIEF and **b** CEX-HPLC. Percent main variants as measured by **c** icIEF and **d** CEX-HPLC. Percent basic variants as measured by **e** icIEF and **f** CEX-HPLC. *CEX-HPLC* cation-exchange high-performance liquid chromatography, *icIEF* imaged capillary isoelectric focusing, *RH* relative humidity

Discussion {#Sec4}
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The stability of 36-months-aged SB5 was evaluated at 0, 2, and 4 weeks of storage at room temperature (25 ± 2 °C) and 60 ± 5% RH. Three batches of SB5 were independently tested for solution appearance, pH, protein concentration, purity, particulate size, biological activity, and charge variance. The results of this study demonstrate that SB5, aged to its shelf-life, is physicochemically and biologically stable for up to 4 weeks at room temperature (25 ± 2 °C) and 60 ± 5% RH, which may indicate longer utility and, in turn, may potentially offer improved convenience in storage.

The color, clarity, and presence of visible particulates of SB5 did not change over time and met acceptance criteria at each time point tested, indicating the absence of large aggregate formation and suggesting that the storage conditions had little to no impact on the quality attributes of SB5. Variations in pH can be responsible for the degradation of monoclonal antibodies \[[@CR14]\]; however, the pH of SB5 also remained stable throughout the 4-week storage period. The lack of significant change in charge variance of SB5 over time was verified using icIEF and CEX-HPLC, which indicated an absence of change to the initial structure. HMW impurities, which are one of the most sensitive indicators of stability, did not increase throughout the 4-week storage period, indicating that SB5 stability is maintained for up to 4 weeks. The total purity of SB5 remained ≥ 95.0%, and the degree of non-glycosylation of antibody heavy chains remained low (no higher than 4.3%) for up to 4 weeks, demonstrating that there was no degradation of the monoclonal antibodies.

The stability of SB5 biological activity over the 4-week period was not changed, as measured by competitive inhibition binding and TNF-alpha neutralization assays. As biological activity is a parameter indicative of efficacy, this maintenance of biological activity may suggest lasting efficacy up to 4 weeks of storage at 25 ± 2 °C and 60 ± 5% RH.

Although this study adopted a broad type of analytical tools to evaluate a stability of aged SB5 under room temperature storage for 4 weeks, microbial testing \[e.g., endotoxins, sterility, container closure integrity (CCI)\] was not conducted in this study as it had previously been determined that CCI was maintained throughout more stringent conditions in previously performed temperature cycling studies (unpublished observations). In these temperature cycling studies, SB5 was exposed to multiple conditions (− 5 °C and 25 °C at 60% RH and 40 °C at 75% RH), and the results met acceptance criteria at each condition. This indicated that the CCI of the microbial barrier would also be maintained under the more moderate conditions used in the present study, which would prevent contamination from other organisms and endotoxins.

Clinical efficacy was also not directly assessed through in vivo testing as part of this study. However, it was confirmed that the stability of SB5 biological activity, which is a parameter indicative of efficacy over the 4-week period, was not changed, as measured by competitive inhibition binding and TNF-alpha neutralization assays. In addition, with consideration of no change in the results for more sensitive phisyco-chemical stability indicating methods, such as SEC, non-reduced CE-SDS, and icIEF, we can conclude that there is no risk of leading to a reduced clinical efficacy.

Biologics are inherently heterogeneous and may vary from batch to batch \[[@CR4]\]. Thus, it is important to ensure that each batch of biologic is highly similar. The results from our study demonstrate that SB5 displayed quality attributes that were similar between batches. Additionally, this similarity was maintained over the 4-week storage period both within and between batches. Although statistical analyses were not performed, the results from each batch and attribute met acceptance criteria, and no trends towards increases or decreases in attributes were observed over the storage period, suggesting that similarity was maintained within this timeframe.

The limitation of this study is not performing microbial testing and in vivo testing to confirm clinical efficacy as part of this study.

Our findings are consistent with a previous study examining the stability of 24-months-aged SB5 (unpublished observations). As biological therapeutics are susceptible to rapid degradation through a variety of biochemical mechanisms \[[@CR15]\], long-term and room-temperature stability are important.

Conclusions {#Sec5}
===========

The stability of SB5, aged to its shelf-life representing a worst-case scenario in terms of medication storage, was evaluated through physico-chemical and biological methods.

The ADA biosimilar SB5 remained stable and biologically active for 4 weeks at room temperature (25 ± 2 °C) and 60 ± 5% RH, with little to no within- or between-batch variability. This stability profile is 2 weeks longer than that of SB5 currently approved in the European Union \[[@CR13]\].
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